# PeptideScanner evidence objects: Retatrutide

Every published version of the records placed with Retatrutide, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/retatrutide.json. Selected public evidence only; not medical advice.

- Objects: 27
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct05882045-retatrutide-v1"></a>

## ClinicalTrials.gov record NCT05882045

> PeptideScanner retained ClinicalTrials.gov record NCT05882045 at 2026-08-10T18:10:03.944Z. Its registry update date was 2026-07-30, and PeptideScanner's reviewed identity mapping was retatrutide.

- Evidence object: `story:clinicaltrials-gov-nct05882045-retatrutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-30
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05882045-retatrutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#clinicaltrials-gov-nct05882045-retatrutide-v1
- Content SHA-256: `70b67ef68adc352017c32d85e578dfd6f8cb32d8ab2037affc5bd8c125be0951`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05882045 ([`ctg-observation-nct05882045-2026-07-30-d21e38ddcccc`](#source-ctg-observation-nct05882045-2026-07-30-d21e38ddcccc))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05882045 at 2026-08-10T18:10:03.944Z. Its registry update date was 2026-07-30, and PeptideScanner's reviewed identity mapping was retatrutide. ([`ctg-observation-nct05882045-2026-07-30-d21e38ddcccc`](#source-ctg-observation-nct05882045-2026-07-30-d21e38ddcccc))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05882045 at 2026-08-10T18:10:03.944Z. Its registry update date was 2026-07-30, and PeptideScanner's reviewed identity mapping was retatrutide. ([`ctg-observation-nct05882045-2026-07-30-d21e38ddcccc`](#source-ctg-observation-nct05882045-2026-07-30-d21e38ddcccc))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05882045-2026-07-30-d21e38ddcccc`](#source-ctg-observation-nct05882045-2026-07-30-d21e38ddcccc))

### Sources

<a id="source-ctg-observation-nct05882045-2026-07-30-d21e38ddcccc"></a>
- **ClinicalTrials.gov record NCT05882045 · retained source version 2026-07-30:d21e38ddcccc7ab66ec1bddaa910bf3c7a7a3149a43f4ac27918a9e80f8452da** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05882045) (`ctg-observation-nct05882045-2026-07-30-d21e38ddcccc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05882045." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#clinicaltrials-gov-nct05882045-retatrutide-v1 SHA-256: 70b67ef68adc352017c32d85e578dfd6f8cb32d8ab2037affc5bd8c125be0951.

---

<a id="clinicaltrials-gov-nct05929066-retatrutide-v1"></a>

## ClinicalTrials.gov record NCT05929066

> PeptideScanner retained ClinicalTrials.gov record NCT05929066 at 2026-09-09T19:17:17.407Z. Its registry update date was 2026-08-21, and PeptideScanner's reviewed identity mapping was retatrutide.

- Evidence object: `story:clinicaltrials-gov-nct05929066-retatrutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-21
- Source checked: 2026-09-09
- Published by PeptideScanner: 2026-09-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05929066-retatrutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#clinicaltrials-gov-nct05929066-retatrutide-v1
- Content SHA-256: `8364bddaf4d34fff478d0528a61f1bf948ebabdc75f41db7ad116db8b2e41cd8`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05929066 ([`ctg-observation-nct05929066-2026-08-21-fa2b7b67fa10`](#source-ctg-observation-nct05929066-2026-08-21-fa2b7b67fa10))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05929066 at 2026-09-09T19:17:17.407Z. Its registry update date was 2026-08-21, and PeptideScanner's reviewed identity mapping was retatrutide. ([`ctg-observation-nct05929066-2026-08-21-fa2b7b67fa10`](#source-ctg-observation-nct05929066-2026-08-21-fa2b7b67fa10))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05929066 at 2026-09-09T19:17:17.407Z. Its registry update date was 2026-08-21, and PeptideScanner's reviewed identity mapping was retatrutide. ([`ctg-observation-nct05929066-2026-08-21-fa2b7b67fa10`](#source-ctg-observation-nct05929066-2026-08-21-fa2b7b67fa10))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05929066-2026-08-21-fa2b7b67fa10`](#source-ctg-observation-nct05929066-2026-08-21-fa2b7b67fa10))

### Sources

<a id="source-ctg-observation-nct05929066-2026-08-21-fa2b7b67fa10"></a>
- **ClinicalTrials.gov record NCT05929066 · retained source version 2026-08-21:fa2b7b67fa10d746247b3082eeaba2f5a16212dc2a870697f3b8369f43983d27** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05929066) (`ctg-observation-nct05929066-2026-08-21-fa2b7b67fa10`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05929066." Version 1, published 2026-09-09. https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#clinicaltrials-gov-nct05929066-retatrutide-v1 SHA-256: 8364bddaf4d34fff478d0528a61f1bf948ebabdc75f41db7ad116db8b2e41cd8.

---

<a id="clinicaltrials-gov-nct05929079-retatrutide-v1"></a>

## ClinicalTrials.gov record NCT05929079

> PeptideScanner retained ClinicalTrials.gov record NCT05929079 at 2026-08-10T18:10:04.224Z. Its registry update date was 2026-07-30, and PeptideScanner's reviewed identity mapping was retatrutide.

- Evidence object: `story:clinicaltrials-gov-nct05929079-retatrutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-30
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05929079-retatrutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#clinicaltrials-gov-nct05929079-retatrutide-v1
- Content SHA-256: `fdffb39c0e3e2760a5d05e44b097c24d46a0f6db907eb003ed425aa0dd2012c9`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05929079 ([`ctg-observation-nct05929079-2026-07-30-d0cad2c0ebfa`](#source-ctg-observation-nct05929079-2026-07-30-d0cad2c0ebfa))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05929079 at 2026-08-10T18:10:04.224Z. Its registry update date was 2026-07-30, and PeptideScanner's reviewed identity mapping was retatrutide. ([`ctg-observation-nct05929079-2026-07-30-d0cad2c0ebfa`](#source-ctg-observation-nct05929079-2026-07-30-d0cad2c0ebfa))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05929079 at 2026-08-10T18:10:04.224Z. Its registry update date was 2026-07-30, and PeptideScanner's reviewed identity mapping was retatrutide. ([`ctg-observation-nct05929079-2026-07-30-d0cad2c0ebfa`](#source-ctg-observation-nct05929079-2026-07-30-d0cad2c0ebfa))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05929079-2026-07-30-d0cad2c0ebfa`](#source-ctg-observation-nct05929079-2026-07-30-d0cad2c0ebfa))

### Sources

<a id="source-ctg-observation-nct05929079-2026-07-30-d0cad2c0ebfa"></a>
- **ClinicalTrials.gov record NCT05929079 · retained source version 2026-07-30:d0cad2c0ebfa7ce1f2af088a52c397680123509e21999e7837a0b2b517e9ef04** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05929079) (`ctg-observation-nct05929079-2026-07-30-d0cad2c0ebfa`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05929079." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#clinicaltrials-gov-nct05929079-retatrutide-v1 SHA-256: fdffb39c0e3e2760a5d05e44b097c24d46a0f6db907eb003ed425aa0dd2012c9.

---

<a id="clinicaltrials-gov-nct05936151-retatrutide-v1"></a>

## ClinicalTrials.gov record NCT05936151

> PeptideScanner retained ClinicalTrials.gov record NCT05936151 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was retatrutide.

- Evidence object: `story:clinicaltrials-gov-nct05936151-retatrutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-09
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05936151-retatrutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#clinicaltrials-gov-nct05936151-retatrutide-v1
- Content SHA-256: `dcff0fe3a5981770aebb7300a4d6c2d5bcc2b62f1efa4d23e4f77ac0dac0d5ec`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05936151 ([`ctg-observation-nct05936151-2026-11-09-cc6ebdc6b830`](#source-ctg-observation-nct05936151-2026-11-09-cc6ebdc6b830))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05936151 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was retatrutide. ([`ctg-observation-nct05936151-2026-11-09-cc6ebdc6b830`](#source-ctg-observation-nct05936151-2026-11-09-cc6ebdc6b830))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05936151 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was retatrutide. ([`ctg-observation-nct05936151-2026-11-09-cc6ebdc6b830`](#source-ctg-observation-nct05936151-2026-11-09-cc6ebdc6b830))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05936151-2026-11-09-cc6ebdc6b830`](#source-ctg-observation-nct05936151-2026-11-09-cc6ebdc6b830))

### Sources

<a id="source-ctg-observation-nct05936151-2026-11-09-cc6ebdc6b830"></a>
- **ClinicalTrials.gov record NCT05936151 · retained source version 2026-11-09:cc6ebdc6b830308f58de4b24fa6555770641df53b168759128c41677cc93236d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05936151) (`ctg-observation-nct05936151-2026-11-09-cc6ebdc6b830`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05936151." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#clinicaltrials-gov-nct05936151-retatrutide-v1 SHA-256: dcff0fe3a5981770aebb7300a4d6c2d5bcc2b62f1efa4d23e4f77ac0dac0d5ec.

---

<a id="clinicaltrials-gov-nct06297603-retatrutide-v1"></a>

## ClinicalTrials.gov record NCT06297603

> PeptideScanner retained ClinicalTrials.gov record NCT06297603 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was retatrutide.

- Evidence object: `story:clinicaltrials-gov-nct06297603-retatrutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-13
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06297603-retatrutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#clinicaltrials-gov-nct06297603-retatrutide-v1
- Content SHA-256: `be7a33a6561cd91470ed3ff87b904b9fb464baed571690798f3ce0774859b989`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06297603 ([`ctg-observation-nct06297603-2026-11-13-c86dcf0120ca`](#source-ctg-observation-nct06297603-2026-11-13-c86dcf0120ca))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06297603 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was retatrutide. ([`ctg-observation-nct06297603-2026-11-13-c86dcf0120ca`](#source-ctg-observation-nct06297603-2026-11-13-c86dcf0120ca))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06297603 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was retatrutide. ([`ctg-observation-nct06297603-2026-11-13-c86dcf0120ca`](#source-ctg-observation-nct06297603-2026-11-13-c86dcf0120ca))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06297603-2026-11-13-c86dcf0120ca`](#source-ctg-observation-nct06297603-2026-11-13-c86dcf0120ca))

### Sources

<a id="source-ctg-observation-nct06297603-2026-11-13-c86dcf0120ca"></a>
- **ClinicalTrials.gov record NCT06297603 · retained source version 2026-11-13:c86dcf0120caf546c9c9fa9df1808025579fcf0e33236ed212dc3df861690ab7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06297603) (`ctg-observation-nct06297603-2026-11-13-c86dcf0120ca`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06297603." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#clinicaltrials-gov-nct06297603-retatrutide-v1 SHA-256: be7a33a6561cd91470ed3ff87b904b9fb464baed571690798f3ce0774859b989.

---

<a id="clinicaltrials-gov-nct06383390-retatrutide-v1"></a>

## ClinicalTrials.gov record NCT06383390

> PeptideScanner retained ClinicalTrials.gov record NCT06383390 at 2026-09-09T19:17:17.103Z. Its registry update date was 2026-08-24, and PeptideScanner's reviewed identity mapping was retatrutide.

- Evidence object: `story:clinicaltrials-gov-nct06383390-retatrutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-24
- Source checked: 2026-09-09
- Published by PeptideScanner: 2026-09-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06383390-retatrutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#clinicaltrials-gov-nct06383390-retatrutide-v1
- Content SHA-256: `d758c697681fc3a8b190b29a31954fbb9606a6530f5a3ad716013c0788b9e175`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06383390 ([`ctg-observation-nct06383390-2026-08-24-4bb37a90f79a`](#source-ctg-observation-nct06383390-2026-08-24-4bb37a90f79a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06383390 at 2026-09-09T19:17:17.103Z. Its registry update date was 2026-08-24, and PeptideScanner's reviewed identity mapping was retatrutide. ([`ctg-observation-nct06383390-2026-08-24-4bb37a90f79a`](#source-ctg-observation-nct06383390-2026-08-24-4bb37a90f79a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06383390 at 2026-09-09T19:17:17.103Z. Its registry update date was 2026-08-24, and PeptideScanner's reviewed identity mapping was retatrutide. ([`ctg-observation-nct06383390-2026-08-24-4bb37a90f79a`](#source-ctg-observation-nct06383390-2026-08-24-4bb37a90f79a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06383390-2026-08-24-4bb37a90f79a`](#source-ctg-observation-nct06383390-2026-08-24-4bb37a90f79a))

### Sources

<a id="source-ctg-observation-nct06383390-2026-08-24-4bb37a90f79a"></a>
- **ClinicalTrials.gov record NCT06383390 · retained source version 2026-08-24:4bb37a90f79acd41fc8e0a5c8b4745c3c9610a0993eab8f502e836929a21c5ff** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06383390) (`ctg-observation-nct06383390-2026-08-24-4bb37a90f79a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06383390." Version 1, published 2026-09-09. https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#clinicaltrials-gov-nct06383390-retatrutide-v1 SHA-256: d758c697681fc3a8b190b29a31954fbb9606a6530f5a3ad716013c0788b9e175.

---

<a id="clinicaltrials-gov-nct07035093-retatrutide-v1"></a>

## ClinicalTrials.gov record NCT07035093

> PeptideScanner retained ClinicalTrials.gov record NCT07035093 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-25, and PeptideScanner's reviewed identity mapping was retatrutide.

- Evidence object: `story:clinicaltrials-gov-nct07035093-retatrutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-25
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07035093-retatrutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#clinicaltrials-gov-nct07035093-retatrutide-v1
- Content SHA-256: `28264f0d30ef76c959feab0c44e910658e3bf6f0e10e62498271a0eaaa6e0413`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07035093 ([`ctg-observation-nct07035093-2026-09-25-27b5bd49e5b2`](#source-ctg-observation-nct07035093-2026-09-25-27b5bd49e5b2))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07035093 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-25, and PeptideScanner's reviewed identity mapping was retatrutide. ([`ctg-observation-nct07035093-2026-09-25-27b5bd49e5b2`](#source-ctg-observation-nct07035093-2026-09-25-27b5bd49e5b2))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07035093 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-25, and PeptideScanner's reviewed identity mapping was retatrutide. ([`ctg-observation-nct07035093-2026-09-25-27b5bd49e5b2`](#source-ctg-observation-nct07035093-2026-09-25-27b5bd49e5b2))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07035093-2026-09-25-27b5bd49e5b2`](#source-ctg-observation-nct07035093-2026-09-25-27b5bd49e5b2))

### Sources

<a id="source-ctg-observation-nct07035093-2026-09-25-27b5bd49e5b2"></a>
- **ClinicalTrials.gov record NCT07035093 · retained source version 2026-09-25:27b5bd49e5b2885416370ca177f51b82402b3ef0b56d13702d26917ac2ced9af** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07035093) (`ctg-observation-nct07035093-2026-09-25-27b5bd49e5b2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07035093." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#clinicaltrials-gov-nct07035093-retatrutide-v1 SHA-256: 28264f0d30ef76c959feab0c44e910658e3bf6f0e10e62498271a0eaaa6e0413.

---

<a id="clinicaltrials-gov-nct07232719-retatrutide-v1"></a>

## ClinicalTrials.gov record NCT07232719

> PeptideScanner retained ClinicalTrials.gov record NCT07232719 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was retatrutide.

- Evidence object: `story:clinicaltrials-gov-nct07232719-retatrutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-10
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07232719-retatrutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#clinicaltrials-gov-nct07232719-retatrutide-v1
- Content SHA-256: `14373e672db7d911b522ab57a9032f50c4458de68eecb749dd4cd527bab21629`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07232719 ([`ctg-observation-nct07232719-2026-11-10-6c54fb96d83e`](#source-ctg-observation-nct07232719-2026-11-10-6c54fb96d83e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07232719 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was retatrutide. ([`ctg-observation-nct07232719-2026-11-10-6c54fb96d83e`](#source-ctg-observation-nct07232719-2026-11-10-6c54fb96d83e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07232719 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was retatrutide. ([`ctg-observation-nct07232719-2026-11-10-6c54fb96d83e`](#source-ctg-observation-nct07232719-2026-11-10-6c54fb96d83e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07232719-2026-11-10-6c54fb96d83e`](#source-ctg-observation-nct07232719-2026-11-10-6c54fb96d83e))

### Sources

<a id="source-ctg-observation-nct07232719-2026-11-10-6c54fb96d83e"></a>
- **ClinicalTrials.gov record NCT07232719 · retained source version 2026-11-10:6c54fb96d83edfdb4971898afdd682f0df573b31ee3c92bfc22a11006e51887a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07232719) (`ctg-observation-nct07232719-2026-11-10-6c54fb96d83e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07232719." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#clinicaltrials-gov-nct07232719-retatrutide-v1 SHA-256: 14373e672db7d911b522ab57a9032f50c4458de68eecb749dd4cd527bab21629.

---

<a id="fda-gram-peptides-warning-letter-v1"></a>

## FDA warning letter names retatrutide and tirzepatide products

> FDA issued a warning letter to Gram Peptides that describes the agency's findings about products marketed with retatrutide and tirzepatide.

- Evidence object: `story:fda-gram-peptides-warning-letter:v1`
- Evidence domain: Regulatory
- Date in source: 2026-03-31
- Source checked: 2026-07-29
- Published by PeptideScanner: 2026-07-29
- Story landing page: https://peptidescanner.com/stories/fda-gram-peptides-warning-letter/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#fda-gram-peptides-warning-letter-v1
- Content SHA-256: `e09356e6e51ecdab0faa56485dbe2778bd69d291f0c129ca144a6830b1a92240`

### Claims and source pins

#### Headline

FDA warning letter names retatrutide and tirzepatide products ([`fda-gram-peptides-warning-letter-2026`](#source-fda-gram-peptides-warning-letter-2026))

#### Summary

FDA issued a warning letter to Gram Peptides that describes the agency's findings about products marketed with retatrutide and tirzepatide. ([`fda-gram-peptides-warning-letter-2026`](#source-fda-gram-peptides-warning-letter-2026))

#### Paragraph 1

The cited FDA warning letter identifies products marketed with retatrutide and tirzepatide and records the agency's stated regulatory findings concerning the recipient. ([`fda-gram-peptides-warning-letter-2026`](#source-fda-gram-peptides-warning-letter-2026))

#### Paragraph 2

A warning letter records FDA's position and requested response at the time it was issued. This update does not generalize those findings to unrelated products or report a later resolution. ([`fda-gram-peptides-warning-letter-2026`](#source-fda-gram-peptides-warning-letter-2026))

### Sources

<a id="source-fda-gram-peptides-warning-letter-2026"></a>
- **FDA warning letter to Gram Peptides** — U.S. Food and Drug Administration; class A. [Open source](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026) (`fda-gram-peptides-warning-letter-2026`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "FDA warning letter names retatrutide and tirzepatide products." Version 1, published 2026-07-29. https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#fda-gram-peptides-warning-letter-v1 SHA-256: e09356e6e51ecdab0faa56485dbe2778bd69d291f0c129ca144a6830b1a92240.

---

<a id="pubmed-pmid-37178114-retatrutide-v1"></a>

## PubMed record PMID 37178114

> PeptideScanner retained PubMed bibliographic metadata for PMID 37178114 at 2026-07-30T16:23:33.798Z. PubMed recorded a metadata revision date of 2026-03-27 and an Entrez history date of 2023-05-13. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-37178114-retatrutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-03-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37178114-retatrutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#pubmed-pmid-37178114-retatrutide-v1
- Content SHA-256: `4ec080ae4ab52c92efab219fda40c8f175a5afdd0b236582abe46cb2e77fae8a`

### Claims and source pins

#### Headline

PubMed record PMID 37178114 ([`pubmed-observation-pmid-37178114-2026-03-27-3cdc53c7f399`](#source-pubmed-observation-pmid-37178114-2026-03-27-3cdc53c7f399))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 37178114 at 2026-07-30T16:23:33.798Z. PubMed recorded a metadata revision date of 2026-03-27 and an Entrez history date of 2023-05-13. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-37178114-2026-03-27-3cdc53c7f399`](#source-pubmed-observation-pmid-37178114-2026-03-27-3cdc53c7f399))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 37178114 at 2026-07-30T16:23:33.798Z. PubMed recorded a metadata revision date of 2026-03-27 and an Entrez history date of 2023-05-13. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-37178114-2026-03-27-3cdc53c7f399`](#source-pubmed-observation-pmid-37178114-2026-03-27-3cdc53c7f399))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37178114-2026-03-27-3cdc53c7f399`](#source-pubmed-observation-pmid-37178114-2026-03-27-3cdc53c7f399))

### Sources

<a id="source-pubmed-observation-pmid-37178114-2026-03-27-3cdc53c7f399"></a>
- **PubMed record PMID 37178114 · retained source version 1:2026-03-27:current:3cdc53c7f399cb19f3dbd197ea70c03ce6be93136abea147a0f3fd16b93acc11** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37178114/) (`pubmed-observation-pmid-37178114-2026-03-27-3cdc53c7f399`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 37178114." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#pubmed-pmid-37178114-retatrutide-v1 SHA-256: 4ec080ae4ab52c92efab219fda40c8f175a5afdd0b236582abe46cb2e77fae8a.

---

<a id="pubmed-pmid-37888925-retatrutide-v1"></a>

## Triple-Hormone-Receptor Agonist Retatrutide for Obesity.

> PubMed lists PMID 37888925 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2023-10-26 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37888925-retatrutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-07-03
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37888925-retatrutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#pubmed-pmid-37888925-retatrutide-v1
- Content SHA-256: `3ceef4667c2832fd9dd468791e3e37f00416c271987336390b790d82ab2b7396`

### Claims and source pins

#### Headline

Triple-Hormone-Receptor Agonist Retatrutide for Obesity. ([`pubmed-observation-pmid-37888925-2025-07-03-b87e839b7f0d`](#source-pubmed-observation-pmid-37888925-2025-07-03-b87e839b7f0d))

#### Summary

PubMed lists PMID 37888925 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2023-10-26 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37888925-2025-07-03-b87e839b7f0d`](#source-pubmed-observation-pmid-37888925-2025-07-03-b87e839b7f0d))

#### Paragraph 1

PubMed lists PMID 37888925 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2023-10-26 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37888925-2025-07-03-b87e839b7f0d`](#source-pubmed-observation-pmid-37888925-2025-07-03-b87e839b7f0d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37888925-2025-07-03-b87e839b7f0d`](#source-pubmed-observation-pmid-37888925-2025-07-03-b87e839b7f0d))

### Sources

<a id="source-pubmed-observation-pmid-37888925-2025-07-03-b87e839b7f0d"></a>
- **Triple-Hormone-Receptor Agonist Retatrutide for Obesity. · retained source version 1:2025-07-03:current:b87e839b7f0d2919fa663ded33830ecd0aa7bac20cbae379414a73c43c6bf563** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37888925/) (`pubmed-observation-pmid-37888925-2025-07-03-b87e839b7f0d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#pubmed-pmid-37888925-retatrutide-v1 SHA-256: 3ceef4667c2832fd9dd468791e3e37f00416c271987336390b790d82ab2b7396.

---

<a id="pubmed-pmid-37888926-retatrutide-v1"></a>

## Triple-Hormone-Receptor Agonist Retatrutide for Obesity.

> PubMed lists PMID 37888926 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2023-10-26 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37888926-retatrutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-07-03
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37888926-retatrutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#pubmed-pmid-37888926-retatrutide-v1
- Content SHA-256: `49ea7105f2b31e544f75f84dc6ab38a405390425260440acfa87c67486016873`

### Claims and source pins

#### Headline

Triple-Hormone-Receptor Agonist Retatrutide for Obesity. ([`pubmed-observation-pmid-37888926-2025-07-03-b72d53d465bd`](#source-pubmed-observation-pmid-37888926-2025-07-03-b72d53d465bd))

#### Summary

PubMed lists PMID 37888926 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2023-10-26 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37888926-2025-07-03-b72d53d465bd`](#source-pubmed-observation-pmid-37888926-2025-07-03-b72d53d465bd))

#### Paragraph 1

PubMed lists PMID 37888926 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2023-10-26 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37888926-2025-07-03-b72d53d465bd`](#source-pubmed-observation-pmid-37888926-2025-07-03-b72d53d465bd))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37888926-2025-07-03-b72d53d465bd`](#source-pubmed-observation-pmid-37888926-2025-07-03-b72d53d465bd))

### Sources

<a id="source-pubmed-observation-pmid-37888926-2025-07-03-b72d53d465bd"></a>
- **Triple-Hormone-Receptor Agonist Retatrutide for Obesity. · retained source version 1:2025-07-03:current:b72d53d465bdbd32536001339546ddb5df25fdfa26c478f1010e16cab430a9d8** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37888926/) (`pubmed-observation-pmid-37888926-2025-07-03-b72d53d465bd`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#pubmed-pmid-37888926-retatrutide-v1 SHA-256: 49ea7105f2b31e544f75f84dc6ab38a405390425260440acfa87c67486016873.

---

<a id="pubmed-pmid-37888927-retatrutide-v1"></a>

## Triple-Hormone-Receptor Agonist Retatrutide for Obesity. Reply.

> PubMed lists PMID 37888927 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2023-10-26 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37888927-retatrutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-07-03
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37888927-retatrutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#pubmed-pmid-37888927-retatrutide-v1
- Content SHA-256: `3ed955d7b430001c5a8ed8ec7060ad27d3899844860a66612ba5d34e777ce530`

### Claims and source pins

#### Headline

Triple-Hormone-Receptor Agonist Retatrutide for Obesity. Reply. ([`pubmed-observation-pmid-37888927-2025-07-03-99a9ba785360`](#source-pubmed-observation-pmid-37888927-2025-07-03-99a9ba785360))

#### Summary

PubMed lists PMID 37888927 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2023-10-26 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37888927-2025-07-03-99a9ba785360`](#source-pubmed-observation-pmid-37888927-2025-07-03-99a9ba785360))

#### Paragraph 1

PubMed lists PMID 37888927 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2023-10-26 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37888927-2025-07-03-99a9ba785360`](#source-pubmed-observation-pmid-37888927-2025-07-03-99a9ba785360))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37888927-2025-07-03-99a9ba785360`](#source-pubmed-observation-pmid-37888927-2025-07-03-99a9ba785360))

### Sources

<a id="source-pubmed-observation-pmid-37888927-2025-07-03-99a9ba785360"></a>
- **Triple-Hormone-Receptor Agonist Retatrutide for Obesity. Reply. · retained source version 1:2025-07-03:current:99a9ba7853606c489dc7e3178591fcfcd9c0129419b674f26c070b90c7a3f411** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37888927/) (`pubmed-observation-pmid-37888927-2025-07-03-99a9ba785360`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity. Reply." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#pubmed-pmid-37888927-retatrutide-v1 SHA-256: 3ed955d7b430001c5a8ed8ec7060ad27d3899844860a66612ba5d34e777ce530.

---

<a id="pubmed-pmid-38323122-retatrutide-v1"></a>

## PubMed record PMID 38323122

> PeptideScanner retained PubMed bibliographic metadata for PMID 38323122 at 2026-08-10T10:49:06.879Z. PubMed recorded a metadata revision date of 2026-07-31 and an Entrez history date of 2024-02-07. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-38323122-retatrutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-31
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38323122-retatrutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#pubmed-pmid-38323122-retatrutide-v1
- Content SHA-256: `692c2ca267944d45d7bc25a6f16ce70bbc3aab87acf730ee86ffdf8043b09110`

### Claims and source pins

#### Headline

PubMed record PMID 38323122 ([`pubmed-observation-pmid-38323122-2026-07-31-09e1a0610186`](#source-pubmed-observation-pmid-38323122-2026-07-31-09e1a0610186))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 38323122 at 2026-08-10T10:49:06.879Z. PubMed recorded a metadata revision date of 2026-07-31 and an Entrez history date of 2024-02-07. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-38323122-2026-07-31-09e1a0610186`](#source-pubmed-observation-pmid-38323122-2026-07-31-09e1a0610186))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 38323122 at 2026-08-10T10:49:06.879Z. PubMed recorded a metadata revision date of 2026-07-31 and an Entrez history date of 2024-02-07. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-38323122-2026-07-31-09e1a0610186`](#source-pubmed-observation-pmid-38323122-2026-07-31-09e1a0610186))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38323122-2026-07-31-09e1a0610186`](#source-pubmed-observation-pmid-38323122-2026-07-31-09e1a0610186))

### Sources

<a id="source-pubmed-observation-pmid-38323122-2026-07-31-09e1a0610186"></a>
- **PubMed record PMID 38323122 · retained source version 1:2026-07-31:current:09e1a061018638d3d88e9c0dbe606d89f2a79d18197e803bbe648799f829c5ae** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38323122/) (`pubmed-observation-pmid-38323122-2026-07-31-09e1a0610186`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 38323122." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#pubmed-pmid-38323122-retatrutide-v1 SHA-256: 692c2ca267944d45d7bc25a6f16ce70bbc3aab87acf730ee86ffdf8043b09110.

---

<a id="pubmed-pmid-39019866-retatrutide-v1"></a>

## Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide.

> PubMed lists PMID 39019866 in Cell discovery as Letter, with publication-date metadata of 2024-07-17 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-39019866-retatrutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-07-20
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39019866-retatrutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#pubmed-pmid-39019866-retatrutide-v1
- Content SHA-256: `54e6416ed5da5f4615f5919daac9ed24487e7eec96179456061c3e22f26cba6c`

### Claims and source pins

#### Headline

Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. ([`pubmed-observation-pmid-39019866-2024-07-20-497b93ace79d`](#source-pubmed-observation-pmid-39019866-2024-07-20-497b93ace79d))

#### Summary

PubMed lists PMID 39019866 in Cell discovery as Letter, with publication-date metadata of 2024-07-17 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39019866-2024-07-20-497b93ace79d`](#source-pubmed-observation-pmid-39019866-2024-07-20-497b93ace79d))

#### Paragraph 1

PubMed lists PMID 39019866 in Cell discovery as Letter, with publication-date metadata of 2024-07-17 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39019866-2024-07-20-497b93ace79d`](#source-pubmed-observation-pmid-39019866-2024-07-20-497b93ace79d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39019866-2024-07-20-497b93ace79d`](#source-pubmed-observation-pmid-39019866-2024-07-20-497b93ace79d))

### Sources

<a id="source-pubmed-observation-pmid-39019866-2024-07-20-497b93ace79d"></a>
- **Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. · retained source version 1:2024-07-20:current:497b93ace79d837dda2b256a32f24f2a382bd85111476943a7b6d1a57b056d33** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39019866/) (`pubmed-observation-pmid-39019866-2024-07-20-497b93ace79d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#pubmed-pmid-39019866-retatrutide-v1 SHA-256: 54e6416ed5da5f4615f5919daac9ed24487e7eec96179456061c3e22f26cba6c.

---

<a id="pubmed-pmid-39429457-retatrutide-v1"></a>

## Retatrutide.

> PubMed lists PMID 39429457 in Clinical diabetes : a publication of the American Diabetes Association as Journal Article, with publication-date metadata of 2024-08-01 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-39429457-retatrutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-09-02
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39429457-retatrutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#pubmed-pmid-39429457-retatrutide-v1
- Content SHA-256: `62e0b786538aeb78a3302221059e03c5a39ae38d4a42379a893c00e496d5a24e`

### Claims and source pins

#### Headline

Retatrutide. ([`pubmed-observation-pmid-39429457-2025-09-02-c4c56d13eeff`](#source-pubmed-observation-pmid-39429457-2025-09-02-c4c56d13eeff))

#### Summary

PubMed lists PMID 39429457 in Clinical diabetes : a publication of the American Diabetes Association as Journal Article, with publication-date metadata of 2024-08-01 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39429457-2025-09-02-c4c56d13eeff`](#source-pubmed-observation-pmid-39429457-2025-09-02-c4c56d13eeff))

#### Paragraph 1

PubMed lists PMID 39429457 in Clinical diabetes : a publication of the American Diabetes Association as Journal Article, with publication-date metadata of 2024-08-01 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39429457-2025-09-02-c4c56d13eeff`](#source-pubmed-observation-pmid-39429457-2025-09-02-c4c56d13eeff))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39429457-2025-09-02-c4c56d13eeff`](#source-pubmed-observation-pmid-39429457-2025-09-02-c4c56d13eeff))

### Sources

<a id="source-pubmed-observation-pmid-39429457-2025-09-02-c4c56d13eeff"></a>
- **Retatrutide. · retained source version 1:2025-09-02:current:c4c56d13eeff24f50c6711af686c5400a993521d67b44b6b64e77b4c5e96506d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39429457/) (`pubmed-observation-pmid-39429457-2025-09-02-c4c56d13eeff`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Retatrutide." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#pubmed-pmid-39429457-retatrutide-v1 SHA-256: 62e0b786538aeb78a3302221059e03c5a39ae38d4a42379a893c00e496d5a24e.

---

<a id="pubmed-pmid-39868848-retatrutide-v1"></a>

## PubMed record PMID 39868848

> PeptideScanner retained PubMed bibliographic metadata for PMID 39868848 at 2026-07-30T16:31:18.163Z. PubMed recorded a metadata revision date of 2026-01-27 and an Entrez history date of 2025-01-27. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-39868848-retatrutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39868848-retatrutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#pubmed-pmid-39868848-retatrutide-v1
- Content SHA-256: `76be691feac2354a02e35b269ae9f352b3b9165a8649a940db45533e71d248b2`

### Claims and source pins

#### Headline

PubMed record PMID 39868848 ([`pubmed-observation-pmid-39868848-2026-01-27-eb810509b913`](#source-pubmed-observation-pmid-39868848-2026-01-27-eb810509b913))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 39868848 at 2026-07-30T16:31:18.163Z. PubMed recorded a metadata revision date of 2026-01-27 and an Entrez history date of 2025-01-27. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-39868848-2026-01-27-eb810509b913`](#source-pubmed-observation-pmid-39868848-2026-01-27-eb810509b913))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 39868848 at 2026-07-30T16:31:18.163Z. PubMed recorded a metadata revision date of 2026-01-27 and an Entrez history date of 2025-01-27. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-39868848-2026-01-27-eb810509b913`](#source-pubmed-observation-pmid-39868848-2026-01-27-eb810509b913))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39868848-2026-01-27-eb810509b913`](#source-pubmed-observation-pmid-39868848-2026-01-27-eb810509b913))

### Sources

<a id="source-pubmed-observation-pmid-39868848-2026-01-27-eb810509b913"></a>
- **PubMed record PMID 39868848 · retained source version 1:2026-01-27:current:eb810509b913f56ae26e02d2de7d545c6834ff92b6069307998ea0a9cbc9a153** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39868848/) (`pubmed-observation-pmid-39868848-2026-01-27-eb810509b913`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 39868848." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#pubmed-pmid-39868848-retatrutide-v1 SHA-256: 76be691feac2354a02e35b269ae9f352b3b9165a8649a940db45533e71d248b2.

---

<a id="pubmed-pmid-40735804-retatrutide-v1"></a>

## PubMed record PMID 40735804

> PeptideScanner retained PubMed bibliographic metadata for PMID 40735804 at 2026-07-30T16:23:38.757Z. PubMed recorded a metadata revision date of 2026-03-07 and an Entrez history date of 2025-07-30. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-40735804-retatrutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-03-07
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40735804-retatrutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#pubmed-pmid-40735804-retatrutide-v1
- Content SHA-256: `71e6320daa9f875cbd50cff8e4fe373ba2b181b89951c8276dc0c824bf81e0c7`

### Claims and source pins

#### Headline

PubMed record PMID 40735804 ([`pubmed-observation-pmid-40735804-2026-03-07-7ef2b2020a72`](#source-pubmed-observation-pmid-40735804-2026-03-07-7ef2b2020a72))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 40735804 at 2026-07-30T16:23:38.757Z. PubMed recorded a metadata revision date of 2026-03-07 and an Entrez history date of 2025-07-30. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-40735804-2026-03-07-7ef2b2020a72`](#source-pubmed-observation-pmid-40735804-2026-03-07-7ef2b2020a72))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 40735804 at 2026-07-30T16:23:38.757Z. PubMed recorded a metadata revision date of 2026-03-07 and an Entrez history date of 2025-07-30. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-40735804-2026-03-07-7ef2b2020a72`](#source-pubmed-observation-pmid-40735804-2026-03-07-7ef2b2020a72))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40735804-2026-03-07-7ef2b2020a72`](#source-pubmed-observation-pmid-40735804-2026-03-07-7ef2b2020a72))

### Sources

<a id="source-pubmed-observation-pmid-40735804-2026-03-07-7ef2b2020a72"></a>
- **PubMed record PMID 40735804 · retained source version 1:2026-03-07:current:7ef2b2020a72aa950adfbeff7db337e5ee11f7c96b0122a59731a78c4aad44bf** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40735804/) (`pubmed-observation-pmid-40735804-2026-03-07-7ef2b2020a72`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 40735804." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#pubmed-pmid-40735804-retatrutide-v1 SHA-256: 71e6320daa9f875cbd50cff8e4fe373ba2b181b89951c8276dc0c824bf81e0c7.

---

<a id="pubmed-pmid-41056349-retatrutide-v1"></a>

## PubMed record PMID 41056349

> PeptideScanner retained PubMed bibliographic metadata for PMID 41056349 at 2026-07-30T16:20:41.592Z. PubMed recorded a metadata revision date of 2026-05-22 and an Entrez history date of 2025-10-07. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41056349-retatrutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-05-22
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41056349-retatrutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#pubmed-pmid-41056349-retatrutide-v1
- Content SHA-256: `a25020a6a1badc43b2530c964f97064f10fcad92a36911e56a3486521310463f`

### Claims and source pins

#### Headline

PubMed record PMID 41056349 ([`pubmed-observation-pmid-41056349-2026-05-22-22478f96609d`](#source-pubmed-observation-pmid-41056349-2026-05-22-22478f96609d))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41056349 at 2026-07-30T16:20:41.592Z. PubMed recorded a metadata revision date of 2026-05-22 and an Entrez history date of 2025-10-07. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41056349-2026-05-22-22478f96609d`](#source-pubmed-observation-pmid-41056349-2026-05-22-22478f96609d))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41056349 at 2026-07-30T16:20:41.592Z. PubMed recorded a metadata revision date of 2026-05-22 and an Entrez history date of 2025-10-07. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41056349-2026-05-22-22478f96609d`](#source-pubmed-observation-pmid-41056349-2026-05-22-22478f96609d))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41056349-2026-05-22-22478f96609d`](#source-pubmed-observation-pmid-41056349-2026-05-22-22478f96609d))

### Sources

<a id="source-pubmed-observation-pmid-41056349-2026-05-22-22478f96609d"></a>
- **PubMed record PMID 41056349 · retained source version 1:2026-05-22:current:22478f96609ddda3ed09bc91ab2eefada074d8f30708385bca05a015bbc6ab22** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41056349/) (`pubmed-observation-pmid-41056349-2026-05-22-22478f96609d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41056349." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#pubmed-pmid-41056349-retatrutide-v1 SHA-256: a25020a6a1badc43b2530c964f97064f10fcad92a36911e56a3486521310463f.

---

<a id="pubmed-pmid-42264536-retatrutide-v1"></a>

## PubMed record PMID 42264536

> PeptideScanner retained PubMed bibliographic metadata for PMID 42264536 at 2026-07-30T16:14:18.135Z. PubMed recorded a metadata revision date of 2026-06-09 and an Entrez history date of 2026-06-09. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42264536-retatrutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-09
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42264536-retatrutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#pubmed-pmid-42264536-retatrutide-v1
- Content SHA-256: `243a588b853d8358b887592a11c520ed3dd32240bfb4c3eb42831c02e1b728cd`

### Claims and source pins

#### Headline

PubMed record PMID 42264536 ([`pubmed-observation-pmid-42264536-2026-06-09-27e8aeb0fa6f`](#source-pubmed-observation-pmid-42264536-2026-06-09-27e8aeb0fa6f))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42264536 at 2026-07-30T16:14:18.135Z. PubMed recorded a metadata revision date of 2026-06-09 and an Entrez history date of 2026-06-09. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42264536-2026-06-09-27e8aeb0fa6f`](#source-pubmed-observation-pmid-42264536-2026-06-09-27e8aeb0fa6f))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42264536 at 2026-07-30T16:14:18.135Z. PubMed recorded a metadata revision date of 2026-06-09 and an Entrez history date of 2026-06-09. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42264536-2026-06-09-27e8aeb0fa6f`](#source-pubmed-observation-pmid-42264536-2026-06-09-27e8aeb0fa6f))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42264536-2026-06-09-27e8aeb0fa6f`](#source-pubmed-observation-pmid-42264536-2026-06-09-27e8aeb0fa6f))

### Sources

<a id="source-pubmed-observation-pmid-42264536-2026-06-09-27e8aeb0fa6f"></a>
- **PubMed record PMID 42264536 · retained source version 1:2026-06-09:current:27e8aeb0fa6fa078dd4029fa4518ce62cef8b7353f54a2c62bc9fd647482b788** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42264536/) (`pubmed-observation-pmid-42264536-2026-06-09-27e8aeb0fa6f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42264536." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#pubmed-pmid-42264536-retatrutide-v1 SHA-256: 243a588b853d8358b887592a11c520ed3dd32240bfb4c3eb42831c02e1b728cd.

---

<a id="pubmed-pmid-42425580-retatrutide-v1"></a>

## PubMed record PMID 42425580

> PeptideScanner retained PubMed bibliographic metadata for PMID 42425580 at 2026-08-10T18:13:55.212Z. PubMed recorded a metadata revision date of 2026-07-09 and an Entrez history date of 2026-07-09. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42425580-retatrutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-09
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42425580-retatrutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#pubmed-pmid-42425580-retatrutide-v1
- Content SHA-256: `2060a6ce2a88309a299ea06085af70a38c43e30010a9e135af3bb8d68a3176a1`

### Claims and source pins

#### Headline

PubMed record PMID 42425580 ([`pubmed-observation-pmid-42425580-2026-07-09-8065da7e05db`](#source-pubmed-observation-pmid-42425580-2026-07-09-8065da7e05db))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42425580 at 2026-08-10T18:13:55.212Z. PubMed recorded a metadata revision date of 2026-07-09 and an Entrez history date of 2026-07-09. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42425580-2026-07-09-8065da7e05db`](#source-pubmed-observation-pmid-42425580-2026-07-09-8065da7e05db))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42425580 at 2026-08-10T18:13:55.212Z. PubMed recorded a metadata revision date of 2026-07-09 and an Entrez history date of 2026-07-09. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42425580-2026-07-09-8065da7e05db`](#source-pubmed-observation-pmid-42425580-2026-07-09-8065da7e05db))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42425580-2026-07-09-8065da7e05db`](#source-pubmed-observation-pmid-42425580-2026-07-09-8065da7e05db))

### Sources

<a id="source-pubmed-observation-pmid-42425580-2026-07-09-8065da7e05db"></a>
- **PubMed record PMID 42425580 · retained source version 1:2026-07-09:current:8065da7e05db89830cd4d089d6deb35ab0d8fdbb1d714a1acbf27995c4d6dd05** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42425580/) (`pubmed-observation-pmid-42425580-2026-07-09-8065da7e05db`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42425580." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#pubmed-pmid-42425580-retatrutide-v1 SHA-256: 2060a6ce2a88309a299ea06085af70a38c43e30010a9e135af3bb8d68a3176a1.

---

<a id="pubmed-pmid-42493254-retatrutide-v1"></a>

## PubMed record PMID 42493254

> PeptideScanner retained PubMed bibliographic metadata for PMID 42493254 at 2026-08-10T18:13:56.730Z. PubMed recorded a metadata revision date of 2026-07-23 and an Entrez history date of 2026-07-23. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42493254-retatrutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-23
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42493254-retatrutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#pubmed-pmid-42493254-retatrutide-v1
- Content SHA-256: `e0f6692b24b513512695dcbd705fa8c402c1c9c6279f4e8969b3468fa906b21f`

### Claims and source pins

#### Headline

PubMed record PMID 42493254 ([`pubmed-observation-pmid-42493254-2026-07-23-1bd98fb63b85`](#source-pubmed-observation-pmid-42493254-2026-07-23-1bd98fb63b85))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42493254 at 2026-08-10T18:13:56.730Z. PubMed recorded a metadata revision date of 2026-07-23 and an Entrez history date of 2026-07-23. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42493254-2026-07-23-1bd98fb63b85`](#source-pubmed-observation-pmid-42493254-2026-07-23-1bd98fb63b85))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42493254 at 2026-08-10T18:13:56.730Z. PubMed recorded a metadata revision date of 2026-07-23 and an Entrez history date of 2026-07-23. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42493254-2026-07-23-1bd98fb63b85`](#source-pubmed-observation-pmid-42493254-2026-07-23-1bd98fb63b85))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42493254-2026-07-23-1bd98fb63b85`](#source-pubmed-observation-pmid-42493254-2026-07-23-1bd98fb63b85))

### Sources

<a id="source-pubmed-observation-pmid-42493254-2026-07-23-1bd98fb63b85"></a>
- **PubMed record PMID 42493254 · retained source version 1:2026-07-23:current:1bd98fb63b85791e1c8b65778d841778e1d7ad574cb700f91fa27ba81b5d3dc1** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42493254/) (`pubmed-observation-pmid-42493254-2026-07-23-1bd98fb63b85`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42493254." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#pubmed-pmid-42493254-retatrutide-v1 SHA-256: e0f6692b24b513512695dcbd705fa8c402c1c9c6279f4e8969b3468fa906b21f.

---

<a id="pubmed-pmid-42527705-retatrutide-v1"></a>

## PubMed record PMID 42527705

> PeptideScanner retained PubMed bibliographic metadata for PMID 42527705 at 2026-08-10T18:13:57.053Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-07-29. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42527705-retatrutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-29
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42527705-retatrutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#pubmed-pmid-42527705-retatrutide-v1
- Content SHA-256: `3e1f846673db0d9361acac965f89b0d8772374ede27ed59c10a458e5f5a4f41c`

### Claims and source pins

#### Headline

PubMed record PMID 42527705 ([`pubmed-observation-pmid-42527705-2026-07-29-28b934ada761`](#source-pubmed-observation-pmid-42527705-2026-07-29-28b934ada761))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42527705 at 2026-08-10T18:13:57.053Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-07-29. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42527705-2026-07-29-28b934ada761`](#source-pubmed-observation-pmid-42527705-2026-07-29-28b934ada761))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42527705 at 2026-08-10T18:13:57.053Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-07-29. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42527705-2026-07-29-28b934ada761`](#source-pubmed-observation-pmid-42527705-2026-07-29-28b934ada761))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42527705-2026-07-29-28b934ada761`](#source-pubmed-observation-pmid-42527705-2026-07-29-28b934ada761))

### Sources

<a id="source-pubmed-observation-pmid-42527705-2026-07-29-28b934ada761"></a>
- **PubMed record PMID 42527705 · retained source version 1:2026-07-29:current:28b934ada7612711a334d69da45b34461f32a691e02e62cd401e173dffb11f78** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42527705/) (`pubmed-observation-pmid-42527705-2026-07-29-28b934ada761`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42527705." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#pubmed-pmid-42527705-retatrutide-v1 SHA-256: 3e1f846673db0d9361acac965f89b0d8772374ede27ed59c10a458e5f5a4f41c.

---

<a id="pubmed-pmid-42567543-retatrutide-v1"></a>

## PubMed record PMID 42567543

> PeptideScanner retained PubMed bibliographic metadata for PMID 42567543 at 2026-08-10T10:49:13.603Z. PubMed recorded a metadata revision date of 2026-08-07 and an Entrez history date of 2026-08-07. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42567543-retatrutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-07
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42567543-retatrutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#pubmed-pmid-42567543-retatrutide-v1
- Content SHA-256: `6fb5847591a48c1ba32b0a14c111031b00436470e801f60f45f87582882e70f0`

### Claims and source pins

#### Headline

PubMed record PMID 42567543 ([`pubmed-observation-pmid-42567543-2026-08-07-6774da56e2dd`](#source-pubmed-observation-pmid-42567543-2026-08-07-6774da56e2dd))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42567543 at 2026-08-10T10:49:13.603Z. PubMed recorded a metadata revision date of 2026-08-07 and an Entrez history date of 2026-08-07. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42567543-2026-08-07-6774da56e2dd`](#source-pubmed-observation-pmid-42567543-2026-08-07-6774da56e2dd))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42567543 at 2026-08-10T10:49:13.603Z. PubMed recorded a metadata revision date of 2026-08-07 and an Entrez history date of 2026-08-07. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42567543-2026-08-07-6774da56e2dd`](#source-pubmed-observation-pmid-42567543-2026-08-07-6774da56e2dd))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42567543-2026-08-07-6774da56e2dd`](#source-pubmed-observation-pmid-42567543-2026-08-07-6774da56e2dd))

### Sources

<a id="source-pubmed-observation-pmid-42567543-2026-08-07-6774da56e2dd"></a>
- **PubMed record PMID 42567543 · retained source version 1:2026-08-07:current:6774da56e2dd75bfa90756dfb327909673dc3c96243572cae10b3c7a51f8701c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42567543/) (`pubmed-observation-pmid-42567543-2026-08-07-6774da56e2dd`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42567543." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#pubmed-pmid-42567543-retatrutide-v1 SHA-256: 6fb5847591a48c1ba32b0a14c111031b00436470e801f60f45f87582882e70f0.

---

<a id="pubmed-pmid-42849462-retatrutide-v1"></a>

## Retatrutide in adults with obesity and type 2 diabetes: what have we learned from TRIUMPH-2?

> PubMed lists PMID 42849462 in Lancet (London, England) as Journal Article, with publication-date metadata of 2026-10-10 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42849462-retatrutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-08
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42849462-retatrutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#pubmed-pmid-42849462-retatrutide-v1
- Content SHA-256: `f262145d0dada64b1d2babd78ceb14be1aca1daa4de656ea583d4d56c4f6734d`

### Claims and source pins

#### Headline

Retatrutide in adults with obesity and type 2 diabetes: what have we learned from TRIUMPH-2? ([`pubmed-observation-pmid-42849462-2026-10-08-8017a2678e67`](#source-pubmed-observation-pmid-42849462-2026-10-08-8017a2678e67))

#### Summary

PubMed lists PMID 42849462 in Lancet (London, England) as Journal Article, with publication-date metadata of 2026-10-10 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42849462-2026-10-08-8017a2678e67`](#source-pubmed-observation-pmid-42849462-2026-10-08-8017a2678e67))

#### Paragraph 1

PubMed lists PMID 42849462 in Lancet (London, England) as Journal Article, with publication-date metadata of 2026-10-10 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42849462-2026-10-08-8017a2678e67`](#source-pubmed-observation-pmid-42849462-2026-10-08-8017a2678e67))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42849462-2026-10-08-8017a2678e67`](#source-pubmed-observation-pmid-42849462-2026-10-08-8017a2678e67))

### Sources

<a id="source-pubmed-observation-pmid-42849462-2026-10-08-8017a2678e67"></a>
- **Retatrutide in adults with obesity and type 2 diabetes: what have we learned from TRIUMPH-2? · retained source version 1:2026-10-08:current:8017a2678e673d781b61acbeb25e29103a8a310c939aa9b13c682a57a025e7e4** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42849462/) (`pubmed-observation-pmid-42849462-2026-10-08-8017a2678e67`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Retatrutide in adults with obesity and type 2 diabetes: what have we learned from TRIUMPH-2?" Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#pubmed-pmid-42849462-retatrutide-v1 SHA-256: f262145d0dada64b1d2babd78ceb14be1aca1daa4de656ea583d4d56c4f6734d.

---

<a id="pubmed-pmid-42853576-retatrutide-v1"></a>

## Unapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain.

> PubMed lists PMID 42853576 in JAMA as Journal Article, with publication-date metadata of 2026-11-03 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42853576-retatrutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-03
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42853576-retatrutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#pubmed-pmid-42853576-retatrutide-v1
- Content SHA-256: `c0a0ace3b1042a8f40fd1c4507a9bcb0160a21d660c71f814c7acf429919f455`

### Claims and source pins

#### Headline

Unapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain. ([`pubmed-observation-pmid-42853576-2026-11-03-1bf66f841ad0`](#source-pubmed-observation-pmid-42853576-2026-11-03-1bf66f841ad0))

#### Summary

PubMed lists PMID 42853576 in JAMA as Journal Article, with publication-date metadata of 2026-11-03 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42853576-2026-11-03-1bf66f841ad0`](#source-pubmed-observation-pmid-42853576-2026-11-03-1bf66f841ad0))

#### Paragraph 1

PubMed lists PMID 42853576 in JAMA as Journal Article, with publication-date metadata of 2026-11-03 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42853576-2026-11-03-1bf66f841ad0`](#source-pubmed-observation-pmid-42853576-2026-11-03-1bf66f841ad0))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42853576-2026-11-03-1bf66f841ad0`](#source-pubmed-observation-pmid-42853576-2026-11-03-1bf66f841ad0))

### Sources

<a id="source-pubmed-observation-pmid-42853576-2026-11-03-1bf66f841ad0"></a>
- **Unapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain. · retained source version 1:2026-11-03:current:1bf66f841ad0b67ede83bbe8cbab027e6d4f32763bc22bdb21f73a8786a3bc13** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42853576/) (`pubmed-observation-pmid-42853576-2026-11-03-1bf66f841ad0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Unapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#pubmed-pmid-42853576-retatrutide-v1 SHA-256: c0a0ace3b1042a8f40fd1c4507a9bcb0160a21d660c71f814c7acf429919f455.

---

<a id="retatrutide-renal-impairment-study-updated-v1"></a>

## Retatrutide renal-impairment study record updated

> ClinicalTrials.gov lists an active, not recruiting Retatrutide study sponsored by Eli Lilly and Company.

- Evidence object: `story:retatrutide-renal-impairment-study-updated:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-20
- Source checked: 2026-07-22
- Published by PeptideScanner: 2026-07-22
- Story landing page: https://peptidescanner.com/stories/retatrutide-renal-impairment-study-updated/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#retatrutide-renal-impairment-study-updated-v1
- Content SHA-256: `7d003be719b2239b9d9e55568e60f98ddb5539477c687a3b1b6b3842bb15d672`

### Claims and source pins

#### Headline

Retatrutide renal-impairment study record updated ([`ctg-nct06297603-v25`](#source-ctg-nct06297603-v25))

#### Summary

ClinicalTrials.gov lists an active, not recruiting Retatrutide study sponsored by Eli Lilly and Company. ([`ctg-nct06297603-v25`](#source-ctg-nct06297603-v25))

#### Paragraph 1

ClinicalTrials.gov lists the NCT06297603 record under Eli Lilly and Company. Its overall recruitment status was shown as active, not recruiting when PeptideScanner reviewed the record. ([`ctg-nct06297603-v25`](#source-ctg-nct06297603-v25))

#### Paragraph 2

The registry shows 2026-07-20 as its latest posted update date. This update reports the registry record and does not establish safety, effectiveness, or a trial outcome. ([`ctg-nct06297603-v25`](#source-ctg-nct06297603-v25))

### Sources

<a id="source-ctg-nct06297603-v25"></a>
- **Retatrutide in Participants With Type 2 Diabetes and Renal Impairment · record history version 25 · last update posted 2026-07-20** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06297603?a=25&tab=history) (`ctg-nct06297603-v25`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Retatrutide renal-impairment study record updated." Version 1, published 2026-07-22. https://peptidescanner.com/evidence/v1/peptides/retatrutide.json#retatrutide-renal-impairment-study-updated-v1 SHA-256: 7d003be719b2239b9d9e55568e60f98ddb5539477c687a3b1b6b3842bb15d672.

